Post Award

News

FDA cancer czar suggests a change to the drug review process

Published December 03, 2013 by OSP


A new process, in which the FDA approves cancer drugs on the basis of which malfunctioning growth pathways they target rather than on what doctors call the resultant condition, has been quietly batted about on the sidelines of conferences or over drinks among oncologists for the past couple years. Although the FDA has not formally proposed any such change, the agency’s cancer czar, Richard Pazdur, recently floated the idea at a public conference on cancer care in Washington, D.C., suggesting the idea may be gaining official traction.

Read More>